T
Tjalf Ziemssen
Researcher at Dresden University of Technology
Publications - 489
Citations - 11537
Tjalf Ziemssen is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 47, co-authored 411 publications receiving 8805 citations. Previous affiliations of Tjalf Ziemssen include University of Tübingen & University of Marburg.
Papers
More filters
Journal ArticleDOI
Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease
Ronald B. Postuma,Dag Aarsland,Paolo Barone,David J. Burn,Christopher Hawkes,Wolfgang H. Oertel,Tjalf Ziemssen +6 more
TL;DR: The evidence for the utility of olfaction, RBD, autonomic markers, visual changes, mood disorders, and cognitive loss as markers of prodromal PD and the potential sensitivity and specificity of these markers are summarized.
Journal ArticleDOI
Stroke-Induced Immunodepression Experimental Evidence and Clinical Relevance
Ulrich Dirnagl,Juliane Klehmet,Johann S. Braun,Hendrik J. Harms,Christian Meisel,Tjalf Ziemssen,Konstantin Prass,Andreas Meisel +7 more
TL;DR: Clinical evidence is emerging demonstrating that stroke-induced immunodepression in humans not only exists, but has very similar features to those characterized in rodent experiments.
Journal ArticleDOI
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
J William L Brown,J William L Brown,J William L Brown,Alasdair Coles,Dana Horakova,Eva Havrdova,Guillermo Izquierdo,Alexandre Prat,Marc Girard,Pierre Duquette,Maria Trojano,Alessandra Lugaresi,Roberto Bergamaschi,Pierre Grammond,Raed Alroughani,Raymond Hupperts,Pamela A. McCombe,Vincent Van Pesch,Patrizia Sola,Diana Ferraro,Francois Grand'Maison,Murat Terzi,Jeannette Lechner-Scott,Schlomo Flechter,Mark Slee,Vahid Shaygannejad,Eugenio Pucci,Franco Granella,Vilija Jokubaitis,Vilija Jokubaitis,Mark Willis,Claire M Rice,Neil J Scolding,Alastair Wilkins,Owen R Pearson,Tjalf Ziemssen,Michael Hutchinson,Katharine Harding,Joanne L. Jones,Christopher McGuigan,Helmut Butzkueven,Helmut Butzkueven,Helmut Butzkueven,Tomas Kalincik,Tomas Kalincik,Neil Robertson +45 more
TL;DR: The probability of conversion was lower when glatiramer acetate or interferon beta was started within 5 years of disease onset vs later, and initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion.
Journal ArticleDOI
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
Christian Schläger,Henrike Körner,Martin Krueger,Stefano Vidoli,Michael Haberl,Dorothee Mielke,Elke Brylla,Thomas B. Issekutz,Carlos Cabañas,Peter J. Nelson,Tjalf Ziemssen,Veit Rohde,Ingo Bechmann,Dmitri Lodygin,Francesca Odoardi,Alexander Flügel +15 more
TL;DR: The data indicate that the leptomeninges represent a checkpoint at which activated T cells are licensed to enter the CNS parenchyma and non-activated T Cells are preferentially released into the CSF, from where they can reach areas of antigen availability and tissue damage.
Journal ArticleDOI
Glatiramer acetate‐specific T‐helper 1‐ and 2‐type cell lines produce BDNF: implications for multiple sclerosis therapy
TL;DR: It is demonstrated that both GA-specific TH2 and TH1 cells produce the neurotrophin brain-derived neurotrophic factor (BDNF), which may be relevant for therapies with altered peptide ligands in general.